Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW

被引：0

作者：

Andre, T. ^{[1
,2
]}

Lonardi, S. ^{[3
]}

Lenz, H. J. ^{[4
]}

Jensen, L. H. ^{[5
]}

Van Cutsem, E. ^{[6
,7
]}

Touchefeu, Y. ^{[8
]}

Garcia-Carbonero, R. ^{[9
]}

Tougeron, D. ^{[10
]}

Mendez, G. A. ^{[11
]}

Schenker, M. ^{[12
]}

de la Fouchardiere, C. ^{[13
]}

Limon, M. L. ^{[14
]}

Yoshino, T. ^{[15
]}

Li, J. ^{[16
]}

Manzano Mozo, J. L. ^{[17
]}

Cela, E. ^{[18
]}

Chen, T. ^{[19
]}

Lei, M. ^{[20
]}

Jin, L. ^{[21
]}

Elez Fernandez, M. E. ^{[22
]}

机构：

[1] Sorbonne Univ, Assistance Publ Hop Paris, Paris, France

[2] Hop St Antoine, Paris, France

[3] Veneto Inst Oncol IOV IRCCS, Med Oncol, Padua, Italy

[4] Univ Southern Calif, Med Oncol Dept, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA

[5] Univ Hosp Southern Denmark, Vejle Hosp, Dept Oncol, Vejle, Denmark

[6] Univ Hosp Gasthuisberg, Digest Oncol Dept, Leuven, Belgium

[7] Univ Leuven, KU Leuven, Leuven, Belgium

[8] Ctr Hosp Univ Nantes, Med Oncol, Nantes, France

[9] UCM, Hosp Univ Octubre Imas12 12, Med Oncol Dept, Madrid, Spain

[10] Ctr Hosp Univ Poitiers, Med Oncol, Poitiers, France

[11] Hosp Univ Fdn Favaloro, Oncol Dept, Buenos Aires, DF, Argentina

[12] Centrul Oncol Sf Nectarie, Med Oncol Dept, Craiova, Romania

[13] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[14] Hosp Univ Virgen Rocio, Oncol Dept, Seville, Spain

[15] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan

[16] Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China

[17] Inst Catala Oncol, Med Oncol, Badalona, Spain

[18] Bristol Myers Squibb, Oncol Global Grp Dev, Princeton, NJ USA

[19] Bristol Myers Squibb, Stats, Princeton, NJ USA

[20] Bristol Myers Squibb, Translat Med, Princeton, NJ USA

[21] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[22] Vall dHebron Univ Hosp & Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.610

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

541P

引用

页码：S451 / S452

页数：2

共 50 条

[1] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
Lenz, Heinz-Josef
Lonardi, Sara
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Manzano, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Joshi, Rohit
Cela, Elvis
Chen, Tian
Jin, Lixian
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
Andre, Thierry
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Lenz, Heinz-Josef
Manzano Mozo, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Cela, Elvis
Yang, Yingsi
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
[3] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Andre, T.
Van Cutsem, E.
Elez, E.
Bennouna, J.
de la Fouchardiere, C.
Yoshino, T.
Jensen, L.
Mendez, G.
Li, J.
Goekkurt, E.
Abdullaev, S.
Chen, T.
Lei, M.
Lonardi, S.
ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
[4] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
Abdullaev, Sandzhar
Andre, Thierry
Lei, Ming
Lenz, Heinz-Josef
Novotny, James
Paulson, Andrew Scott
Tejpar, Sabine
Yamazaki, Kentaro
Ledeine, Jean-Marie
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[5] Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Lonardi, S.
Andre, T.
Arnold, D.
Garcia-Carbonero, R.
Chalabi, M.
Elez Fernandez, M. E.
Lenz, H. J.
Jensen, L. H.
Joshi, R.
Roodhart, J. M. L.
Yoshino, T.
Dixon, M.
Blum, S. I.
Sims, J.
Lawrance, R.
Taylor, F.
Chen, T.
Cela, E.
Jin, L.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2024, 35 : S1 - S2
[6] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
Andre, Thierry
Elez, Elena
Lenz, Heinz-Josef
Jensen, Lars Henrik
Touchefeu, Yann
Van Cutsem, Eric
Garcia-Carbonero, Rocio
Tougeron, David
Mendez, Guillermo
Schenker, Michael
de la Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Aubin, Francine
Cela, Elvis
Chen, Tian
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
[7] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
Emidio, O.
Iqbal, Z.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
[8] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, M. Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Cardin, Dana Backlund
Spallanzani, Andrea
Dragovich, Tomislav
Shah, Usman
Atasoy, Ajlan
Ledeine, Jean-Marie
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
Yang, Jing
Ledeine, Jean-Marie
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, Maria Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen
Wang, Rui
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 97 - 97

← 1 2 3 4 5 →